Targeting a blood protein involved in clotting during inflammation
Differential targeting of von Willebrand factor depending on oxidizing conditions
['FUNDING_R01'] · UNIVERSITY OF WASHINGTON · NIH-10875626
This study is looking at how a blood protein called von Willebrand factor acts during inflammation, with the goal of finding new treatments that can help prevent dangerous blood clots while still allowing your body to clot normally when needed.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF WASHINGTON (nih funded) |
| Locations | 1 site (SEATTLE, UNITED STATES) |
| Trial ID | NIH-10875626 on ClinicalTrials.gov |
What this research studies
This research investigates how the blood protein von Willebrand factor (VWF) behaves under inflammatory conditions, particularly focusing on its ability to bind to blood platelets and initiate clotting. By understanding the changes that occur in VWF due to oxidation during inflammation, the researchers aim to develop targeted therapies that can prevent harmful blood clots while allowing normal clotting to occur. The approach involves laboratory experiments to identify specific binding sites on VWF that can be selectively targeted in inflammatory environments, potentially leading to safer anti-thrombotic treatments.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with conditions that involve excessive blood clotting, particularly in inflammatory contexts.
Not a fit: Patients who do not have issues related to blood clotting or inflammation may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that prevent dangerous blood clots without increasing the risk of bleeding.
How similar studies have performed: Previous research has shown promise in targeting blood proteins for therapeutic purposes, but this specific approach focusing on VWF under oxidative conditions is relatively novel.
Where this research is happening
SEATTLE, UNITED STATES
- UNIVERSITY OF WASHINGTON — SEATTLE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: INTERLANDI, GIANLUCA — UNIVERSITY OF WASHINGTON
- Study coordinator: INTERLANDI, GIANLUCA
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.